DIAGENS-B(02526.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 55.88 million, loss widened by 4070.37% YoY

NewTimeSpace News: August 07, 2026, DIAGENS-B(02526.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 108.69 million, increased by 21.03% YoY; Net Profit stood at loss of CNY 55.88 million, loss widened by 4070.37% YoY; Profit Attributable to Shareholders stood at loss of CNY 55.88 million, loss widened by 4070.37% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.66.

By the close of trading on August 07, 2026, DIAGENS-B(02526) saw a gain of 0.05% in its share price, closing at HKD 418. The full-day turnover stood at HKD 5.88 million, with the latest market capitalization at HKD 37.15 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.